Key Points
Phase III REDeS study met primary efficacy and safety endpoints.
Kit sales represented 90% of third-quarter fibrinogen complex product shipments.
North American product revenue grew 12% year over year.
On its third quarter of 2026 earnings call, held on Nov. 2, 2026, Cerus (NASDAQ:CERS) announced top-line results from its Phase III REDeS study for red blood cell pathogen reduction. The medical device maker's expanding its target market while converting direct hospital sales into higher-margin kit distribution. Positive cash flow from operations reached $3 million as international device placements picked up. Three insights from management explain how the strategy's unfolding.
1. Red Blood Cell Trial Meets Primary Endpoints
Expanding pathogen reduction technology to red blood cells creates the largest new market opportunity in the company's history. The Phase III REDeS study evaluated safety and efficacy across patients requiring acute and long-term blood transfusions, proving the treated blood performs as well as standard red blood cells without added clinical risk.
REDeS met its primary efficacy endpoint, demonstrating non inferiority in adjusted hemoglobin increment compared with conventional red blood cells.
-- Vivek K. Jayaraman, President and Chief Executive Officer
2. Kit Conversion Drives Higher Gross Margins
Management's shifting INTERCEPT Fibrinogen Complex (ISC), a blood component used for severe bleeding, from finished therapeutic sales to a kit-based distribution model. Customer blood centers process the kits directly, which expands hospital distribution while boosting gross margin, the proportion of sales remaining after direct production costs, because kit sales are accretive, meaning they improve overall profit margins.
While the finished biologics carry a higher selling price, the gross margin profile for our kit model is accretive to our consolidated gross margins.
-- Kevin D. Green, Chief Financial Officer
3. BCA Partnership Expands Core North American Adoption
A nationwide distribution agreement with Blood Centers of America (BCA), a network managing over half of U.S. blood products, is accelerating adoption. By leveraging BCA's established sales network, management deepens customer relationships across both platelets and pathogen-reduction kits without expanding its internal sales force.
Through the first 3 quarters of the year, revenue growth from BCA member blood centers outpaced overall North American growth.
-- Vivek K. Jayaraman, President and Chief Executive Officer
Looking Ahead
International placements of the INT200 Illuminator device are outpacing internal expectations and setting up future kit sales. Cerus relies on exclusive blood center partnerships and expanding hospital adoption for long-term growth, while management focuses on regulatory submissions and working capital efficiency.
We are generating strong growth across our core franchises, we are successfully transitioning our ISC business model, and our international rollout of the INT200 Illuminator is exceeding expectations.
-- Vivek K. Jayaraman, President and Chief Executive Officer
Line of sight toward profitability under Generally Accepted Accounting Principles (GAAP), standard accounting rules, builds financial self-sufficiency for clinical development.
As an organization, we are committed to looking beyond adjusted EBITDA and have line of sight into achieving GAAP profitability.
-- Kevin D. Green, Chief Financial Officer
The Motley Fool has positions in and recommends Cerus. The Motley Fool has a disclosure policy.